NK-cellsTo develop the most successful novel agents for cancer, researchers require preclinical models that fundamentally epitomize patient populations to enable predictive outcomes. Patient-derived models represent a considerable advantage over traditional models of cancer to expedite drug development. In this webinar, Amy Wesa, PhD, of Champions Oncology Inc, will discuss how complementing these translational PDX models with the introduction of human immune cells is driving the next generation of patient-derived models.

Next Generation Humanized Mice

View this webinar to learn:

  • The latest advances in human immune system mouse models for oncology therapeutics
  • The power of primary patient-derived models for acute myeloid leukemia (AML)
  • Novel methods for evaluating natural killer (NK) cell therapeutics of cancer in humanized mice

Presenter:

Amy WesaAmy Wesa, PhD, is the Director of Immuno-Oncology Research at Champions Oncology Inc. Dr. Wesa oversees the research and development of innovative patient-derived platforms in oncology, including immuno-oncology platforms, humanized mouse models, hematologic malignancy PDX models, and ex vivo patient-derived models of cancer for translational drug development. With over 15 years of experience in translational immuno-oncology spanning industry and academia, she is an expert in cell and gene therapy, including CAR T cell therapies for solid and hematologic malignancies. A previous American Cancer Society Research Scholar, Dr. Wesa is the author of over 20 peer-reviewed publications and has been the PI on multiple grants. Dr. Wesa holds a BS in Biology from the University of Michigan in Ann Arbor, a PhD in Cancer Biology from Wayne State University School of Medicine, and completed her postdoctoral training in Tumor Immunology at the University of Pittsburgh Cancer Institute.


View Now »

View Now

   
© 2020 Taconic Biosciences, Inc. All rights reserved.

© 2020 Taconic Biosciences, Inc. All rights reserved.